Is UHS a good stock to buy? We came across a bullish thesis on Universal Health Services, Inc. on r/ValueInvesting by Dynaheir-be. In this article, we will summarize the bulls’ thesis on UHS. Universal Health Services, Inc.’s share was trading at $150.12 as of May 28th. UHS’s trailing and forward P/E were 6.44 and 6.56 respectively according to Yahoo Finance.
smart.art/Shutterstock.com
Universal Health Services (NYSE:UHS) is one of the largest for-profit hospital operators in the United States, operating acute care hospitals alongside a large behavioral health network across the US, UK, and Puerto Rico. Acute care remains the stable cash flow engine, while behavioral health provides a secular growth driver supported by rising demand for mental health services.
Read More: 15 AI Stocks That Are Quietly Making Investors Rich
Read More: Undervalued AI Stock Poised For Massive Gains: 10000% Upside Potential
The Miller family’s supervoting control structure reinforces a long-term, conservative capital allocation framework. In 2025, the company generated $17.4 billion in revenue, up 9.7%, with operating margins expanding to about 11.5% from 10.6%, reflecting pricing power and disciplined cost management.
Q1 2026 continued this momentum, with revenue up 9.6% to $4.5 billion and EPS rising to $5.65 from $4.80, while net leverage improved to 1.70x from 2.00x. Despite this strong operating performance, the stock trades at multi-year lows due to Medicaid policy fears, creating a clear disconnect between fundamentals and valuation.
Operating cash flow reached $401.6 million in Q1 2026, while capital allocation remains highly shareholder-focused, with $899 million in buybacks in 2025 and $127 million in Q1 2026, signaling management’s confidence in intrinsic value. The Talkspace acquisition expands virtual behavioral health capabilities and is expected to be accretive within a year. 2026 guidance implies $18.4 to $18.8 billion in revenue, or 6 to 8% growth, supported by improving utilization trends.
A $900 million credit capacity expansion reduces liquidity risk, while litigation and reserve charges remain largely contained within insurance coverage limits. The bull case centers on a rerating as Medicaid concerns normalize, leverage continues to decline, and earnings visibility improves, unlocking multiple expansion for a high-quality healthcare compounder trading at depressed levels despite consistent execution.
Previously, we covered a bullish thesis on DaVita Inc. (DVA) by Isaac459 in February 2025, which highlighted the potential recovery in dialysis volumes driven by improving mortality trends and post-pandemic normalization. DVA’s stock price has appreciated by approximately 14.59% since our coverage. Dynaheir-be shares a similar view but emphasizes UHS valuation disconnect, Medicaid fears, and capital allocation strength.
